Amir Hefni is the CEO of Resolution Therapeutics. Prior to joining Resolution, he was the Global Head of Cell and Gene Therapy at Novartis and had end to end responsibility for the platform. Previously, he was a Global Asset Head in Oncology at Ipsen and spent most of his career at Bristol-Myers Squibb with senior positions across US Oncology, General Management and Strategy & Operations for key markets. Amir holds a BSc and PhD in Pharmacology from King’s College London and an MBA from Warwick Business School.